Japan Specialist

Mark Chadwick

Equity Bottom-Up

<ul>
<li>Kao has the lonest period of consecutive earnings growth in the Nikkei's new "Consecutive Dividend Growth Stock Index"</li>
<li>With a 2.8% yield and a long history of raising its dividend, Kao should definitely be on the income investor's radar screen</li>
<li>Despite the recent underperformance of the stock (-4% ytd), Kao does not represent compelling valuations</li>
</ul>


Kao has the lonest period of consecutive earnings growth in the Nikkei's new "Consecutive Dividend Growth Stock Index"
With a 2.8% yield and a long history of raising its dividend, Kao should definitely be on the income investor's radar screen
Despite the recent underperformance of the stock (-4% ytd), Kao does not represent compelling valuations


Kao (4452) | Is It Time to Buy This Dividend Aristocrat?

Value Investing

Vladimir Dimitrov, CFA

Estee Lauder Companies Cl A / Equity Bottom-Up

<ul>
<li>Estée Lauder continues to make new lows as risks related to its premium valuation and business concentration materialize.</li>
<li>Estée Lauder's return on capital is also facing long-lasting headwinds.</li>
<li>The company will remain too richly priced for the time being, according to the company's CEO.</li>
</ul>


Estée Lauder continues to make new lows as risks related to its premium valuation and business concentration materialize.
Estée Lauder's return on capital is also facing long-lasting headwinds.
The company will remain too richly priced for the time being, according to the company's CEO.


Estee Lauder: Premium Valuations Are Not Always Justified

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Estee Lauder had a mixed quarter.</li><li>Its organic net sales fell by 8% but its retail sales growth outpaced organic sales growth in numerous areas resulting in the company surpassing the revenue expectations of analysts.</li><li>Encouragingly, retail sales performance in global travel retail is far ahead of organic sales results.</li></ul>

Estee Lauder had a mixed quarter.Its organic net sales fell by 8% but its retail sales growth outpaced organic sales growth in numerous areas resulting in the company surpassing the revenue expectations of analysts.Encouragingly, retail sales performance in global travel retail is far ahead of organic sales results.

The Estee Lauder Companies Inc.: Retail Sales in Global Travel Retail

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Event-Driven

<ul>
<li>Giant Biogene raised around US$70m in its Hong Kong IPO, after having downsized the deal and priced it at the low-end. Its six-month lockup will expire soon.</li>
<li>GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.</li>
<li>In this note, we will talk about the lock-up dynamics and updates since our last note.</li>
</ul>


Giant Biogene raised around US$70m in its Hong Kong IPO, after having downsized the deal and priced it at the low-end. Its six-month lockup will expire soon.
GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
In this note, we will talk about the lock-up dynamics and updates since our last note.


Giant Biogene IPO Lock-Up - US$1.7bn Lockup Release Will Increase Free Float by 14x

Equity Capital Markets

<ul>
<li>Honasa Consumer (HC) is looking to raise about US$350m in its upcoming India IPO.</li>
<li>HC’s product portfolio includes products in the baby care, face care, body care, hair care, color cosmetics and fragrances segments.</li>
<li>In this note, we will talk about the not-so-positive aspects of the deal.</li>
</ul>


Honasa Consumer (HC) is looking to raise about US$350m in its upcoming India IPO.
HC’s product portfolio includes products in the baby care, face care, body care, hair care, color cosmetics and fragrances segments.
In this note, we will talk about the not-so-positive aspects of the deal.


Honasa Consumer Pre-IPO - The Negatives - Ad Spending Keeping Profits Low

United States

The Estee Lauder Companies Inc. manufactures and markets a wide range of skin care, makeup, fragrance, and hair care products.  The Company's products are sold in countries and territories around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Estee Lauder Companies Cl A (EL US)

Kao (4452) | Is It Time to Buy This Dividend Aristocrat?

Kao has the lonest period of consecutive earnings growth in the Nikkei's new "Consecutive Dividend Growth Stock Index". With a dividend yield of...

Mark Chadwick

Estee Lauder: Premium Valuations Are Not Always Justified

Estée Lauder continues to make new lows as risks related to its premium valuation and business concentration materialize. Estée Lauder's return on...

Vladimir Dimitrov, CFA

The Estee Lauder Companies Inc.: Retail Sales in Global Travel Retail

Estee Lauder had a mixed quarter. Its organic net sales fell by 8% but its retail sales growth outpaced organic sales growth in numerous areas...

Baptista Research

Giant Biogene IPO Lock-Up - US$1.7bn Lockup Release Will Increase Free Float by 14x

Giant Biogene raised around US$70m in its Hong Kong IPO, after having downsized the deal and priced it at the low-end. Its six-month lockup will...

Sumeet Singh

Honasa Consumer Pre-IPO - The Negatives - Ad Spending Keeping Profits Low

Honasa Consumer (HC) is looking to raise about US$350m in its upcoming India IPO. In this note, we talk about the not-so-positive aspects of the deal.

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)